Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Last Updated: June 10, 2023

CLINICAL TRIALS PROFILE FOR VESANOID

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

All Clinical Trials for Vesanoid

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005825 ↗	Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer	Unknown status	Raghu Nandan, M.D., Inc	Phase 2	1998-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
NCT00006220 ↗	Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	1999-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells. PURPOSE: Phase I/II trial to study the effectiveness of arsenic trioxide with or without tretinoin in treating patients who have hematologic cancer that has not responded to previous therapy.
NCT00006220 ↗	Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy	Terminated	Washington University School of Medicine	Phase 1/Phase 2	1999-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells. PURPOSE: Phase I/II trial to study the effectiveness of arsenic trioxide with or without tretinoin in treating patients who have hematologic cancer that has not responded to previous therapy.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Vesanoid

Condition Name

Chart
Table

Condition Name for Vesanoid
Intervention	Trials
Myelodysplastic Syndrome	3
Acute Myelogenous Leukemia	3
Leukemia	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Vesanoid
Intervention	Trials
Leukemia	10
Leukemia, Myeloid, Acute	7
Preleukemia	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Vesanoid

Trials by Country

Map
Table

Trials by Country for Vesanoid
Location	Trials
United States	69
Australia	6
Canada	6
New Zealand	2
United Kingdom	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Vesanoid
Location	Trials
Texas	6
Ohio	3
Oregon	3
California	3
Colorado	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Vesanoid

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Vesanoid
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	10
Phase 1/Phase 2	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Vesanoid
Clinical Trial Phase	Trials
Completed	8
Recruiting	5
Active, not recruiting	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vesanoid

Sponsor Name

Chart
Table

Sponsor Name for Vesanoid
Sponsor	Trials
Celgene Corporation	4
M.D. Anderson Cancer Center	4
National Cancer Institute (NCI)	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Vesanoid
Sponsor	Trials
Other	36
Industry	9
NIH	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey

Harvard Business School

Johnson and Johnson

AstraZeneca

Merck

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.